Avelumab plus axitinib (A plus Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial

被引：0

作者：

Oya, M. ^{[1
]}

Motzer, R. J. ^{[2
]}

Choueiri, T. K. ^{[3
]}

Haanen, J. B. A. G. ^{[4
]}

Eto, M. ^{[5
]}

Uemura, H. ^{[6
]}

Venugopal, B. ^{[7
]}

Rini, B. I. ^{[8
]}

Miyake, H. ^{[9
]}

Albiges, L. ^{[10
]}

Schmidinger, M. ^{[11
]}

Tomita, Y. ^{[12
,13
]}

Umeyama, Y. ^{[14
]}

Ellers-Lenz, B. ^{[15
]}

Hoffman, J. ^{[16
]}

Larkin, J. ^{[17
]}

机构：

[1] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[4] Netherlands Canc Inst, Amsterdam, Netherlands

[5] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan

[6] Kindai Univ, Fac Med, Dept Urol, Osakasayama, Japan

[7] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[8] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[9] Kobe Univ, Grad Sch Med, Div Urol, Kobe, Hyogo, Japan

[10] Inst Gustave Roussy, Villejuif, France

[11] Med Univ Vienna, Vienna, Austria

[12] Niigata Univ, Grad Sch Med, Dept Urol, Niigata, Japan

[13] Niigata Univ, Grad Sch Med, Dept Mol Oncol, Niigata, Japan

[14] Pfizer Japan Inc, Clin & Res Dept, Oncol, Shibuya Ku, Tokyo, Japan

[15] Merck Healthcare KGaA, Darmstadt, Germany

[16] EMD Serono Res & Dev Inst Inc, Billerica, MA USA

[17] Royal Marsden Hosp, London, England

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.312

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

292P

引用

页码：S1517 / S1518

页数：2

共 50 条

[21] Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): results from JAVELIN Renal 101
Grimm, Marc-Oliver
Oya, Mototsugu
Choueiri, Toni K.
Schmidinger, Manuela
Quinn, David
Gravis-Mescam, Gwenaelle
Verzoni, Elena
Van den Eertwegh, Alfonsus
Di Pietro, Alessandra
Mariani, Mariangela
Wang, Jing
Thomaidou, Despina
Albiges, Laurence
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 100 - 100
[22] Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
Choueiri, T. K.
Motzer, R. J.
Rini, B., I
Haanen, J.
Campbell, M. T.
Venugopal, B.
Kollmannsberger, C.
Gravis-Mescam, G.
Uemura, M.
Lee, J. L.
Grimm, M-O
Gurney, H.
Schmidinger, M.
Larkin, J.
Atkins, M. B.
Pal, S. K.
Wang, J.
Mariani, M.
Krishnaswami, S.
Cislo, P.
Chudnovsky, A.
Fowst, C.
Huang, B.
di Pietro, A.
Albiges, L.
ANNALS OF ONCOLOGY, 2020, 31 (08) : 1030 - 1039
[23] Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
Zhang, Yue
Wu, Shenhong
TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S585 - S588
[24] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
Tomita, Yoshihiko
Motzer, Robert J.
Choueiri, Toni K.
Rini, Brian I.
Miyake, Hideaki
Oya, Mototsugu
Albiges, Laurence
Fujii, Yosuke
Umeyama, Yoshiko
Wang Jing
Di Pietro, Alessandra
Schmidinger, Manuela
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[25] C-reactive protein (CRP) as a predictive marker for outcomes with avelumab plus axitinib (A plus Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101.
Tomita, Yoshihiko
Motzer, Robert J.
Choueiri, Toni K.
Rini, Brian I.
Uemura, Hirotsugu
Oya, Mototsugu
Albiges, Laurence
Fujii, Yosuke
Umeyama, Yoshiko
Huang, Bo
Di Pietro, Alessandra
Schmidinger, Manuela
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[26] Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
Haanen, J. B. A. G.
Larkin, J.
Choueiri, T. K.
Albiges, L.
Rini, B. I.
Atkins, M. B.
Schmidinger, M.
Penkov, K.
Michelon, E.
Wang, J.
Mariani, M.
di Pietro, A.
Motzer, R. J.
ESMO OPEN, 2023, 8 (03)
[27] First-line avelumab plus axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
Choueiri, Toni K.
Larkin, James M. G.
Oya, Mototsugu
Thistlethwaite, Fiona C.
Martignoni, Marcella
Nathan, Paul D.
Powles, Thomas
McDermott, David F.
Robbins, Paul B.
Chism, David D.
Cho, Daniel C.
Atkins, Michael B.
Gordon, Michael S.
Gupta, Sumati
Uemura, Hirotsugu
Tomita, Yoshihiko
Compagnoni, Anna
Di Pietro, Alessandra
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, Robert J.
Penkov, Konstantin
Haanen, John
Rini, Brian
Albiges, Laurence
Campbell, Matthew T.
Venugopal, Balaji
Kollmannsberger, Christian
Negrier, Sylvie
Uemura, Motohide
Lee, Jae L.
Vasiliev, Aleksandr
Miller, Wilson H., Jr.
Gurney, Howard
Schmidinger, Manuela
Larkin, James
Atkins, Michael B.
Bedke, Jens
Alekseev, Boris
Wang, Jing
Mariani, Mariangela
Robbins, Paul B.
Chudnovsky, Aleksander
Fowst, Camilla
Hariharan, Subramanian
Huang, Bo
di Pietro, Alessandra
Choueiri, Toni K.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1103 - 1115
[29] Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Bilen, Mehmet A.
Rini, Brian, I
Voss, Martin H.
Larkin, James
Haanen, John B. A. G.
Albiges, Laurence
Pagliaro, Lance C.
Voog, Eric G.
Lam, Elaine T.
Kislov, Nikolay
McGregor, Bradley A.
Lalani, Aly-Khan A.
Huang, Bo
di Pietro, Alessandra
Krulewicz, Stan
Robbins, Paul B.
Choueiri, Toni K.
CLINICAL CANCER RESEARCH, 2022, 28 (04) : 738 - 747
[30] Association of C-reactive protein (CRP) with efficacy of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.
Tomita, Yoshihiko
Larkin, James
Venugopal, Balaji
Haanen, John B. A. G.
Kanayama, Hiro-Omi
Eto, Masatoshi
Grimm, Marc-Oliver
Fujii, Yosuke
Umeyama, Yoshiko
Mariani, Mariangela
Di Pietro, Alessandra
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →